Cytokine and chemokine blockade as immunointervention strategy for the treatment of diffuse lung diseases

Sarcoidosis Vasculitis and Diffuse Lung Diseases

Volumn 18, Issue 1, 2001, Pages 18-22

  Agostini, C ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Antagonists and inhibitors; Chemokines; Cytokines; Diffuse lung diseases; IL 15; Monoclonal antibodies; Tumor necrosis factor

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR; CYTOKINE; CYTOKINE RECEPTOR; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

CROHN DISEASE; DISEASE ACTIVITY; DRUG EFFICACY; DRUG TOLERABILITY; GRANULOMA; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOTHERAPY; INFLAMMATION; INTERSTITIAL LUNG DISEASE; LUNG ALVEOLITIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SARCOIDOSIS; TISSUE INJURY;

ANTIBODIES, MONOCLONAL; CHEMOKINES; CLINICAL TRIALS; CYTOKINES; HUMANS; INFLAMMATION; LUNG DISEASES, INTERSTITIAL; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035073248     PISSN: 11240490     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Cells and cytokines involved in the pathogenesis of sarcoidosis
2. Infliximab in refractory sarcoidosis
3. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other granulomatous disorders
4. The role of tumor necrosis factor in health and disease
5. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy
6. Anti-cytokine therapy for rheumatoid arthritis
7. Anti-TNF antibody treatment of Crohn's disease
8. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial
9. Cytokine blockade as a new strategy to treat rheumatoid arthritis: Inhibition of tumor necrosis factor
10. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
11. Release of tumor necrosis factor by alveolar macrophages of patients with sarcoidosis
12. Increased expression of proinflammatory chemokines in bronchoalveolar lavage cells of patients with progressing idiopathic pulmonary fibrosis and sarcoidosis
13. Production of the RANTES chemokine in delayed-type hypersensitivity reactions: Involvement of macrophages and endothelial cells
14. Elevated IL-8 and MCP-1 in the bronchoalveolar lavage fluid of patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis
15. Macrophage inflammatory protein-1 alpha expression in interstitial lung disease
16. Involvement of the IP-10 chemokine in sarcoid granulomatous reactions
17. The CXC chemokines, IL-8 and IP- 10, regulate angiogenic activity in idiopathic pulmonary fibrosis
18. Monocyte chemoattractant protein 1-dependent leukocytic infiltrates are responsible for autoimmune disease in MRL-Fas(1pr) mice
19. Defects in the generation of IFN-gamma are overcome to control infection with Leishmania donovani in CC chemokine receptor (CCR) 5-, macrophage inflammatory protein-1 alpha-, or CCR2-deficient mice
20. T cell infiltration into class II MHC-disparate allografts and acute rejection is dependent on the IFN-gamma-induced chemokine Mig
21. Role of IL-15, IL-2, and their receptors in the development of T cell alveolitis in pulmonary sarcoidosis
22. Interleukin-15 (IL-15) induces IL-8 and monocyte chemotactic protein 1 production in human monocytes
23. High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism
24. Antigen presentation in the lung: Dendritic cells and macrophages
25. Selective blockade of IL-15 by soluble IL-15 receptor alpha-chain enhances cardiac allograft survival
26. Humanized antibodies against the alpha-chain of the IL-2 receptor and against the beta-chain shared by the IL-2 and IL-15 receptors in a monkey uveitis model of autoimmune diseases